New Research Group studying Myelodysplastic Syndromes at the Josep Carreras Leukaemia Research Institute
The Josep Carreras Leukaemia Research Institute has opened a new line of research and Francesc Solé, specialist in cytogenetic diagnostics of hematological neoplasms, has joined the team
Dr Francesc Solé is specialized in cytogenetic diagnostics of hematological neoplasms has joined the IJC and from today he will be directing a new project centered on Myelodysplastic Syndromes.
Previously, Dr Solé was directing the Molecular Cytogenetics Laboratory for the Pathology Service in the Hospital del Mar in Barcelona, where he studied the genetic reorganization present in various malignant hemopathologies. Together with Dr Lourdes Florensa he led the Translational Research Group for Hematological Neoplasms (GRETNHE) of the IMIM at the Biomedical Park of Barcelona (PRBB). From 1998 t 2004 Dr Solé was the president of the Spanish Cooperative Group for Hematological Cytogenetics, part of the Spanish Association for Hematology and Hemotherapy (AEHH). This has been part of the IWG-PM ("International Working Group of Prognostics in Myelodysplastic Syndromes)" since 2008.
The group's line of work will concentrate on genetic changes that can be used for diagnostics or prognostics. Currently, knowing the karyotype is the best tool for knowing the prognosis. They will also run the cytogenetics platform providing a diagnostics service.
Knowing the details of genetic changes will provide more information on the mechanisms of the disease, which in turn will provide opportunities for new treatments. Myelodysplastic syndromes have an incidence of 3-5 cases per 100,000 people a year according to the World Health Organization. They are particularly prevalent in older people and many people diagnosed go on to develop a leukemia.